ACE1831

ACE1831 is an allogeneic, off-the-shelf gamma delta T cell therapy developed by Acepodia. It utilizes bioorthogonal chemistry to conjugate anti-CD20 antibodies (notably rituximab) to γδ2 T cells, creating a non-genetically engineered cellular immunotherapy. This approach enables targeted cytotoxicity against CD20-expressing malignant B cells and is designed to overcome limitations of autologous CAR-T therapies, such as manufacturing complexity and severe side effects like cytokine release syndrome or neurotoxicity. Preclinical and early clinical data show potent in vitro and in vivo activity against B-cell lymphomas with a favorable safety profile. The therapy is being evaluated for relapsed/refractory non-Hodgkin’s lymphoma (including follicular lymphoma, marginal zone B-cell lymphoma, mediastinal large B-cell lymphoma) and has received FDA IND clearance for immunoglobulin G4-related disease (IgG4-RD). Development involves collaboration with Pfizer Ignite[1][3][4][5][6][7].

Other names

anti-CD20 antibody-conjugated allogeneic gamma delta T cell therapyanti-CD-20 antibody-conjugated allogeneic gamma delta T cell therapyanti-CD 20 antibody-conjugated allogeneic gamma delta T cell therapyCD20-conjugated allogeneic gamma delta T cell therapyCD-20-conjugated allogeneic gamma delta T cell therapyCD 20-conjugated allogeneic gamma delta T cell therapyaCD20-conjugated Vδ2 gamma delta T cellsCD20-γδ T cells